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KEY POINTS 
1.      TP53 deletion of minor tumour sub-clones is independently prognostic in newly diagnosed 
multiple myeloma.    
2.      Assessment of sub-clonal TP53 deletions by MLPA is readily applicable in standard 
diagnostics, enabling stratified patient management. 
 
ABSTRACT 
Multiple myeloma (MM) is a genetically heterogeneous cancer of bone marrow plasma cells with 
variable outcome. To assess the prognostic relevance of clonal heterogeneity of TP53 copy 
number, we profiled tumours from 1,777 newly diagnosed Myeloma XI trial patients with 
multiplex ligation-dependent probe amplification (MLPA). Sub-clonal TP53 deletions were 
independently associated with shorter overall survival with a hazard ratio of 1.8 (95% CI: 1.2-2.8; 
P=0.01). Clonal, but not sub-clonal, TP53 deletion were associated with clinical markers of 
advanced disease, specifically lower platelet counts (P<0.001) and increased LDH (P<0.001), and 
higher frequency of features indicative of genomic instability del(13q)(P=0.002) or 
del(1p)(P=0.006). Bi-allelic TP53 loss-of-function by mutation and deletion was rare (2.4%) and 
associated with advanced disease. We present a framework for identifying sub-clonal TP53 
deletions by MLPA, to improve patient stratification in MM and tailor therapy, enabling 
management strategies.  
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INTRODUCTION 
 
Despite recent improvements in survival, patient outcomes remain variable in multiple myeloma 
(MM). It is increasingly recognised that tumour heterogeneity is a determinant of patient outcome 
for many cancers and the identification of sub-clonal driver events is central to better patient 
stratification
1,2
. Aberrations of TP53 are recognised to be one of most important markers of poor 
prognosis in MM
3
. These are secondary driver events with variable sub-clonal distribution with 
TP53 typically being deleted and point mutations being relatively rare
4
. Defining the prognostic 
association of sub-clonal deletion of TP53 in MM at diagnosis and a cut-off for diagnostic purposes 
has however been problematic due to the technical challenges of using interphase fluorescence in 
situ hybridisation (iFISH) in MM to quantify sub-clonal populations
5
. To assess the prognostic 
relevance of sub-clonal TP53 deletion at diagnosis, we profiled 1,777 MM trial patients using 
multiplex ligation dependent probe amplification (MLPA), which is readily applicable in diagnostic 
settings.   
 
METHODS 
Myeloma IX and XI trial patients 
We studied 1,777 patients with MM enrolled in the UK NCRI Myeloma XI trial and a subset from 
MRC Myeloma IX  and Myeloma XI underwent comparison of MLPA and iFISH (Supplementary 
Methods). 
 
Copy number, translocation calling and mutation detection 
Bone marrow aspirates were processed as detailed in Supplementary Methods. Details about 
iFISH profiling of Myeloma IX and Myeloma XI have been published previously and described in 
Supplementary Methods
6
. Myeloma XI cases were profiled for copy number by MLPA and 
translocations determined by quantitative PCR as previously reported
7
.  
 
The MLPA P425-probemix (MRC-Holland) interrogates TP53 exons 4, 7 and 10. TP53 was 
considered deleted when normalised copy number values of two of three MLPA probes were 
below the defined cut-off. 1,357 patient tumours were further analysed with probemix X073, 
covering all exons of TP53. Previously published exome-sequencing was available for 463 
patients
4
.   
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Statistical analysis 
Statistical analyses were performed in R (version 3.4.1) using sub-routines survival, survC1 and 
survivalROC. Progression-free survival (PFS) was defined as time from randomisation to 
progression or death and overall survival (OS) as time from randomization to death. To define 
the optimal prognostic normalised MLPA cut-off value for TP53 deletion calling, we analysed 
sub-groups defined by descending (0.05 steps from 1.0 (equivalent to normal diploid copy 
number)) normalised MLPA value using time-dependent Receiver Operater Curve AUCi 
estimates for OS for each cut-off
8
. 
 
Cox proportional hazards regression was used to estimate univariate and multivariable hazard 
ratios (HRs) and 95% confidence intervals (CI). Kaplan–Meier survival curves were generated and 
homogeneity between groups was assessed using the log-rank test. Association between 
categorical variables was examined using the Fishers exact test and between continuous 
variables using the Wilcoxon signed-rank test. A two-sided P-value <0.05 was considered 
significant.  
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RESULTS AND DISCUSSION 
 
To identify the clinically relevant threshold for sub-clonal TP53 deletions we interrogated step-
wise increasing fractions of TP53 deletion by MLPA using the time-dependent ROC curve analysis 
method (AUCi) for OS
9
.  We identified a normalised TP53 MLPA value of <0.8 as the cut-off 
providing optimal prognostic power, identifying 192 of 1,777 (10.8%) tumours as TP53 deleted 
(Supplementary Figure 1). These results were consistent in intensively (transplant eligible) and 
non-intensively treated patients (non-transplant eligible) (Supplementary Table 1). The optimised 
<0.8 MLPA cut-off is equivalent to 10-20% sub-clonal 17p deletion, lower MLPA levels <0.6 were 
equivalent to clonal deletions with ≥50% tumour fraction and MLPA values <0.5 were equivalent 
to fully clonal (95-100%) del(17p) when compared to iFISH in a matched dataset from the 
Myeloma IX
6
 and Myeloma XI trial (Supplementary Figure 2b) . The distribution of MLPA 
normalised values for TP53 probes across 1,777 Myeloma XI tumours is shown in Supplementary 
Figure 2. Inclusion of sub-clonal deletions by MLPA <0.8 cut-off was confirmed as prognostically 
most informative by univariate Kaplan-Meier log-rank testing (P=6.7x10
-15
), Cox regression (Wald 
P=4.1x10
-14
) and C-statistics by Uno et al
10
 (Supplementary Table 2). A limitation of the study is 
the lack of a validation trial dataset.  
 
Treatment allocation, key demographics and induction response were comparable between 
patients with TP53-deleted and non-deleted tumours as defined by MLPA <0.8. Patients with TP53 
deletion, however showed features of advanced disease and associated morbidity, specifically 
reduced platelet counts <150x10
9
/l (P=5.1x10
-4
) and poorer performance status (WHO ≥2) 
(P=0.0012) (Supplementary Table 3). Although WHO was independently associated with shorter 
survival, the association with WHO and TP53 deletion suggests an inter-relationship with genetic 
and clinical features that are normally thought of as patient related rather than disease related.  
 
To characterise features of sub-clonal versus clonal deletion, TP53 deleted tumours were grouped 
into 3 equal-sized sub-groups based on MLPA values: sub-clonally deleted (n=67; MLPA cut-off 
≥0.7<0.8), intermediate clonal (n=64; MLPA ≥0.55<0.7) and clonally TP53 deleted tumours (n=61; 
MLPA <0.55). All three groups were independently associated with OS with sub-clonally deleted 
HR of 1.8 (95% CI: 1.2-2.8; P=0.01) for OS, intermediate deleted HR 2.9 (95% CI: 1.9-4.4; 
P=5.6x10
-7
) and clonally deleted HR 2.2 (CI: 1.4-3.2; P=0.0002) (Figure 1: a and b; 
Supplementary Table 4). Landmarked analyses from autologous stem cell transplant and 
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lenalidomide maintenance randomisation show consistent results for all three groups (Figure 1:  
c and d; Supplementary Table 4). 
 
Correlating clinical characteristics, patients with clonal rather than sub-clonal TP53 deletion were 
associated with markers of high disease burden, specifically reduced platelet <150x10
9
/l (35% vs 
9%; P=0.00047) and high LDH level >300U/l (57% vs. 32%; P=0.012) (Figure 2b). Clonal vs. 
subclonal deletion of TP53 was associated with higher rates of del(13q) (68% vs. 40%; P=0.002) 
and/or del(1p) (21% vs. 4%; P=0.006) (Figure 2a). The rate of TP53 mutations were increased in 
clonal (3/18) vs sub-clonal deletions (1/21). Although MLPA cannot comprehensively assess 
clonal architecture, an association between TP53 deletion clonality with increasing size of 
del(13q) clone (P=0.002) (Figure 2 c, d; Supplementary Figure 5) raise the possibility of co-
evolution of these lesions. Deletion of TP53 and RB1 on chromosome 13q have been shown to 
be important in cell cycle
11
 and senescence
12
 suggesting possible mechanisms of how their co-
deletion may confer a competitive advantage.  
 
Clonal homozygous TP53 deletions defined by MLPA values <0.25 were present in nine of 1,777 
tumours (0.5%) analysed with the P425 MLPA probemix for exons 4, 7 and 10 of TP53. To identify 
patterns of focal homozygous deletions, all eleven TP53 exons were analysed using a specifically 
designed X073 MLPA probe-mix in 1,357 patients. Homozygous deletion frequency was low (0.6%) 
and deletions were focal and not restricted to the DNA binding domain of TP53. Homozygous TP53 
deletion was associated with very short median OS of 22.4 months and a HR for OS of 3.7 (95% CI: 
1.5-8.9; P=0.004) (Supplementary Figure 3; Supplementary Table 5). Most patients with 
homozygous TP53 deletions had markers of clinically and molecularly advanced disease with 
elevated LDH >300U/l in 67%, reduced platelet counts <150x10
9
/l (67%) and del(13q) in 88% of 
cases. Exome-sequencing data was available for 422 of the MLPA profiled tumours. Of these, ten 
tumours (2.4%) had bi-allelic (mutation+deletion) TP53 loss-of-function and 47 tumours (11.1%) 
mono-allelic loss. Bi- and mono-allelic TP53 loss were independently associated with inferior 
survival (Supplementary Figure 3, Supplementary Table 5).  
 
In summary, we demonstrate independent association of sub-clonal TP53 deletions with MM 
outcome. Sub-clonal TP53 deletion detection by MLPA is readily applicable within diagnostic 
settings and could enable stratified treatment approaches aiming at preventing subsequent rapid 
disease evolution. 
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Figure Legends 
Figure 1: Association between sub-clonal and clonal TP53 deletion and survival in newly 
diagnosed myeloma. Kaplan Meier survival curves showing (a) PFS and (b) OS of 3 approximately 
equal sized TP53 deleted clonal subgroups versus no TP53 deletion in 1777 patients in the 
Myeloma XI trial (c) OS evaluation of above subgroups in landmarked analysis from time of high-
dose melphalan and autologous stem cell transplant (d) OS evaluation of above subgroups in 
landmarked analysis from time of maintenance randomisation.   
Figure 2: Relationship between sub-clonal and clonal TP53 deletion with clinical and genetic 
characteristics of myeloma. Percentage frequency of (a) genetic changes associated with low, 
intermediate and high deletion of TP53 clone (b) clinical changes associated with low, 
intermediate and high deletion of TP53 clone (c) MLPA values normalised values for 13q probes in 
the same patients with low, intermediate and high deletion of TP53 clone (d) MLPA values across 
subset of patients with del(TP53) in patients with increasing size of del(13q) clone. Lower MLPA 
values represent increasing size of deleted clone.   
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